Claims
- 1. Compounds of the general formula (I)
- 2. Compounds of the general formula (I),
in which A represents a bond or represents a —CH2— or —CH2CH2— group, X represents O, S or CH2, R1, R2 and R3 are identical or different and independently of one another each represents hydrogen, (C1-C6)-alkyl, (C1-C6)-alkoxy, hydroxyl, halogen, trifluoromethyl, trifluoromethoxy, nitro or cyano, R4 represents hydrogen or (C1-C4)-alkyl, R5 and R6 each represents hydrogen or together with the carbon atom to which they are attached form a carbonyl group, R7 represents hydrogen, (C1-C6)-alkyl, phenyl or benzyl, in which the aromatic radicals mentioned for their part may in each case be mono- to trisubstituted by identical or different substituents from the group consisting of (C1-C6)-alkyl, (C1-C6)-alkoxy, hydroxyl or halogen, R8 represents hydrogen, (C6-C10)-aryl or (C1-C4)-alkyl, which for its part is optionally substituted by (C6-C10)-aryl or 5- or 6-membered heteroaryl having up to three heteroatoms from the group consisting of N, O and S, where all of the ring systems mentioned may for their part in each case be mono- to trisubstituted by identical or different substituents from the group consisting of halogen, hydroxyl, (C1-C6)-alkyl, (C1-C6)-alkoxy, trifluoromethyl, trifluoromethoxy, cyano, nitro and amino, R9 and R10 are identical or different and independently of one another each represents hydrogen, (C1-C6)-alkyl, (C1-C6)-alkoxy, trifluoromethyl, trifluoromethoxy or halogen, R11 and R12 are identical or different and independently of one another each represents hydrogen or (C1-C6)-alkyl, or together with the carbon atom to which they are attached they form a (C4-C7)-cycloalkyl ring, and R13 represents hydrogen or a group that can be hydrolysed and degraded to the corresponding carboxylic acid, and their pharmaceutically acceptable salts, hydrates and solvates.
- 3. Compounds of the general formula (I) according to claim 1 or 2,
in which A represents a —CH2— or —CH2CH2— group, X represents O, S or CH2, R1, R2 and R3 are identical or different and independently of one another each represents hydrogen, (C1-C4)-alkyl, (C1-C4)-alkoxy, chlorine, fluorine, trifluoromethyl, trifluoromethoxy, nitro or cyano, R4 represents hydrogen or methyl, R5 and R6 each represent hydrogen or together with the carbon atom to which they are attached form a carbonyl group, R7 represents hydrogen, (C1-C4)-alkyl or benzyl, R8 represents hydrogen, phenyl, benzyl or 5-membered heteroarylmethyl having up to two heteroatoms from the group consisting of N, O and S, where the aromatic ring systems mentioned for their part may in each case be mono- to trisubstituted by identical or different substituents from the group consisting of chlorine, fluorine, bromine, hydroxyl, (C1-C4)-alkyl, (C1-C4)-alkoxy, trifluoromethyl and amino, R9 and R10 are identical or different and independently of one another each represents hydrogen, (C1-C3)-alkyl, (C1-C3)-alkoxy, trifluoromethyl, fluorine or chlorine, R11 and R12 are identical or diffferent and independently of one another each represents hydrogen, methyl or ethyl, or together with the carbon atom to which they are attached they form a cyclopentyl or cyclohexyl ring, and R13 represents hydrogen or represents a group that can be hydrolysed and degraded to the corresponding carboxylic acid, and their pharmaceutically acceptable salts, hydrates and solvates.
- 4. Compounds of the general formula (I), according to claim 1, 2 or 3in which A represents a —CH2— or —CH2CH2— group, X represents O, S or CH2, R1 represents hydrogen, methyl or methoxy, R2 and R3 are identical or different and independently of one another each represents methyl, trifluoromethyl, methoxy, trifluoromethoxy, chlorine or fluorine, R4 represents hydrogen, R5 and R6 together with the carbon atom to which they are attached form a carbonyl group, R7 represents methyl, ethyl, n-propyl or, in particular, hydrogen, R8 represents phenyl, furanylmethyl or thienylmethyl, where the ring systems mentioned for their part may in each case be mono- or disubstituted by identical or different substituents from the group consisting of methyl and ethyl, R9 and R10 are identical or different and each represents hydrogen or methyl in particular hydrogen, R11 and R12 are identical or different and each represents hydrogen or methyl in particular methyl, and R13 represents a group which can be hydrolysed and degraded to the corresponding carboxylic acid, or, in particular, represents hydrogen, and their pharmaceutically acceptable salts, hydrates and solvates.
- 5. Compounds of the formula (IA)
- 6. Compounds of the formula (I) as defined in claims 1 to 5 for the prophylaxis and treatment of diseases.
- 7. Medicaments, comprising at least one compound of the formula (I) as defined in claim 1 and inert nontoxic, pharmaceutically suitable carriers, auxiliaries, solvents, vehicles, emulsifiers and/or dispersants.
- 8. Use of compounds of the formula (I) and medicaments as defined in claims 1 to 7 for the prophylaxis and treatment of diseases.
- 9. Use of compounds of the formula (I) as defined in claims 1 to 6 for preparing medicaments.
- 10. Use of compounds of the formula (I) as defined in claims 1 to 6 for preparing medicaments for the treatment of arteriosclerosis.
- 11. Method for the prophylaxis and treatment of diseases, characterized in that compounds of the formula (I) as defined in claim 1 are allowed to act on living beings.
- 12. Process for preparing medicaments, characterized in that at least one compound of the formula (I) as defined in claim 1 is converted into an administration form using auxiliaries and/or carriers.
- 13. Process for preparing compounds of the formula (I) as defined in claim 1, characterized in that
[A] compounds of the general formula (II) 185 in which
A, X, R7, R8, R9, R10, R11 and R12 are each as defined above and T represents benzyl, (C1-C6)-alkyl or a polymeric support suitable for solid-phase synthesis, are initially, with activation of the carboxylic acid group in (II), reacted with compounds of the general formula (II) 186in which R1, R2 and R3 are each as defined above, to give compounds of the general formula (Ia) 187in which A, X, T, R1, R2, R3, R7, R8, R9, R10, R11 and R12 are each as defined above, or [B] compounds of the general formula (IV) 188 in which
A, X, T, R8, R9, R10, R11 and R12 are each as defined above are, in the presence of a base, reacted with compounds of the general formula (V) 189in which R1, R2, R3 and R7 are each as defined above and Q is a suitable leaving group, likewise to compounds of the general formula (Ia) the compounds of the general formula (Ia) are, if appropriate according to known methods for amide alkylation or amide reduction, converted into compounds of the general formula (Ib) 190in which A, X, T, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are each as defined above, then converted with acids or bases into the corresponding carboxylic acids of the general formula (Ic) 191in which A, X, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are each as defined above, and these are, if appropriate according to known methods for esterification, modified further by reaction with compounds of the general formula (VI)R13—Z (VI),in which R13 is as defined above and Z represents a suitable leaving group or represents a hydroxyl group.
- 14. Use according to claim 9 for preparing medicaments for the treatment of arteriosclerosis, for increasing pathologically low HDL levels and for reducing elevated triglyceride and LDL levels in cases of arteriosclerosis and/or hypercholesterolaemia.
- 15. Use of compounds of the formula (I) as defined in claim 1 as agonists of the peroxisome-proliferator-activated receptor.
- 16. Compounds of the formula (II)
Priority Claims (1)
Number |
Date |
Country |
Kind |
101 24 905.5 |
May 2001 |
DE |
|
Parent Case Info
[0001] This application is a continuing application of U.S. Ser. No. 10/349,448, filed Jan. 22, 2003, which is a continuing application of U.S. Ser. No. 09/973,753, filed Oct. 9, 2001, now U.S. Pat. No. 6,548,538.
Continuations (2)
|
Number |
Date |
Country |
Parent |
10349448 |
Jan 2003 |
US |
Child |
10797311 |
Mar 2004 |
US |
Parent |
09973753 |
Oct 2001 |
US |
Child |
10349448 |
Jan 2003 |
US |